Drug Type TCR-T Cell therapy |
Synonyms |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | United States | 21 Jul 2022 | |
Breast Cancer | Preclinical | United States | 21 Jul 2022 | |
Colorectal Cancer | Preclinical | United States | 21 Jul 2022 | |
Head and Neck Neoplasms | Preclinical | United States | 21 Jul 2022 | |
Lung Cancer | Preclinical | United States | 21 Jul 2022 | |
Melanoma | Preclinical | United States | 21 Jul 2022 | |
Ovarian Cancer | Preclinical | United States | 21 Jul 2022 | |
Prostatic Cancer | Preclinical | United States | 21 Jul 2022 |